Domekouo Ulrich L F, Longo Frida, Tarkang Protus A, Tchinda Alembert T, Tsabang Nole, Donfagsiteli Nehemie T, Tamze Victorine, Kamtchouing Pierre, Agbor Gabriel A
Department of Animal Biology and Physiology, University of Yaoundé I, Cameroon.
Laboratoire de Physiologie Animale de l'Ecole Normale Supérieure, Université de Yaoundé I, Cameroun.
Pak J Pharm Sci. 2016 May;29(3):903-11.
The present research evaluated the antidiabetic and antioxidant properties of M. lucida stem bark (50 and 500mg/kg) and glibenclamide (25mg/kg, standard drug) in acute (Oral glucose tolerance test) and sub-acute (Streptozotocin 60mg/kg, i.p. diabetic model) administration. A group of healthy rats constituted the normal control. The sub-acute experiment lasted 28 days during which water, food intake and weight gain were measured and biochemical parameters analyzed in both plasma and erythrocytes at the end of the experiment. The chemical substances present in M. lucida bark extract were determined. In the Oral glucose tolerance test, the reduction of blood glucose level was statistically significant for both M. lucida extracts and glibenclamide. However, in the diabetic rats acute administration of 500mg/kg extract had better blood sugar lowering effect than glibenclamide, which was better than 50mg/kg extract. Streptozotocin diabetic animal model was characterized by a decrease in weight gain, erythrocyte SOD and CAT activities and an increase in water and food consumption, lipid peroxidation, cholesterol, triglycerides, plasma glucose, creatinine and urea concentrations, and transaminases activities. M. lucida extract and glibenclamide significantly prevented the alteration of these parameters, thus indicating a corrective effect on diabetes and its complications. This study justifies the traditional claim and provides a rationale for the use of M. lucida to treat diabetes. Its antioxidant properties may serve to curb oxidative stress and hence prevent the diabetic complications related to oxidative stress. Chemical substances, which may be accountable for the antidiabetic and antioxidant properties of M. lucida were detected in the aqueous extract of M. lucida bark.
本研究评估了光亮楝（M. lucida）茎皮（50和500mg/kg）及格列本脲（25mg/kg，标准药物）在急性（口服葡萄糖耐量试验）和亚急性（腹腔注射链脲佐菌素60mg/kg糖尿病模型）给药时的抗糖尿病和抗氧化特性。一组健康大鼠作为正常对照。亚急性实验持续28天，在此期间测量水、食物摄入量和体重增加情况，并在实验结束时分析血浆和红细胞中的生化参数。测定了光亮楝树皮提取物中存在的化学物质。在口服葡萄糖耐量试验中，光亮楝提取物和格列本脲对血糖水平的降低均具有统计学意义。然而，在糖尿病大鼠中，急性给予500mg/kg提取物的降血糖效果优于格列本脲，后者又优于50mg/kg提取物。链脲佐菌素糖尿病动物模型的特征是体重增加减少、红细胞超氧化物歧化酶（SOD）和过氧化氢酶（CAT）活性降低，以及水和食物消耗增加、脂质过氧化、胆固醇、甘油三酯、血浆葡萄糖、肌酐和尿素浓度升高，转氨酶活性增加。光亮楝提取物和格列本脲显著预防了这些参数的改变，从而表明对糖尿病及其并发症具有纠正作用。本研究证实了传统说法，并为使用光亮楝治疗糖尿病提供了理论依据。其抗氧化特性可能有助于抑制氧化应激，从而预防与氧化应激相关的糖尿病并发症。在光亮楝树皮水提取物中检测到了可能对光亮楝的抗糖尿病和抗氧化特性负责的化学物质。
